A Delphi Study of Core Patient-Reported Outcomes for Advanced Renal Cell Carcinoma and Advanced Hepatocellular Carcinoma

被引:1
|
作者
de la Serna, Celia Diez de los Rios [1 ]
Drury, Amanda [2 ]
Oldenmenger, Wendy H. [3 ]
Kelly, Daniel [4 ]
Kotronoulas, Grigorios [5 ]
机构
[1] European Oncol Nursing Soc EONS, Oncol Adv Nurse Practitioner, Brussels, Belgium
[2] Dublin City Univ, Sch Nursing Psychotherapy & Community Hlth, Dublin, Ireland
[3] Univ Med Ctr, Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[4] Cardiff Univ, Sch Healthcare Sci, Cardiff, Wales
[5] Univ Glasgow, Sch Med Dent & Nursing, Glasgow City, Scotland
关键词
Patient-reported outcomes; Advanced renal cell carcinoma; Cancer; Advanced hepatocellular carcinoma; Quality of life; Person-centered care; QUALITY-OF-LIFE; CANCER; PROS; CARE;
D O I
10.1016/j.soncn.2023.151409
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: There is little research to help health care professionals understand what patient outcomes are considered a priority in advanced liver or kidney cancer. Knowing what is important to patients can help pro-mote person-centered approaches to treatment and disease management. The aim of this study was to identify those patient-reported outcomes (PROs) that patients, carers, and health care professionals consider as "core" when providing care to those with advanced liver or kidney cancer.Data sources: A three-round Delphi study was undertaken to ask experts by profession or experience to rank PROs identified from a previous literature review. Fifty-four experts, including people living with advanced liver or kidney cancer (44.4%), family members and caregivers (9.3%), and health care professionals (46.8%), reached consensus on 49 PROs including 12 new items (eg, palpitations, hopefulness, or social isolation). Items with the highest rate of consensus included quality of life, pain, mental health, and capacity to do daily activities.Conclusion: People living with advanced liver or kidney cancer experience complex health care needs. Some important outcomes were not actually captured in practice in this population and were suggested as part of this study. There are discrepancies between the views of health care professionals, patients, and family in what is important, highlighting the need of using measures to facilitate communication. Implications for Nursing Practice: Identification of priority PROs reported here will be key to facilitate more focused patient assessments. The actual use of measures in cancer nursing practice to allow monitoring of PROs must be tested for feasibility and usability.& COPY; 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Everolimus In Advanced Renal Cell Carcinoma
    Garnock-Jones, Karly P.
    Keating, Gillian M.
    DRUGS, 2009, 69 (15) : 2115 - 2124
  • [42] TemsirolimusIn Advanced Renal Cell Carcinoma
    Dene Simpson
    Monique P. Curran
    Drugs, 2008, 68 : 631 - 638
  • [43] PazopanibIn Advanced Renal Cell Carcinoma
    Mark Sanford
    Gillian M. Keating
    BioDrugs, 2010, 24 : 279 - 286
  • [44] EverolimusIn Advanced Renal Cell Carcinoma
    Karly P. Garnock-Jones
    Gillian M. Keating
    Drugs, 2009, 69 : 2115 - 2124
  • [45] Milestones in advanced renal cell carcinoma
    Niedersuess-Beke D.
    memo - Magazine of European Medical Oncology, 2017, 10 (1) : 38 - 41
  • [46] Immunotherapy for advanced renal cell carcinoma
    Aulitzky, WE
    Kaufmann, M
    UROLOGE A, 2004, 43 (01): : 85 - 92
  • [47] Imaging of advanced renal cell carcinoma
    Ullrich G. Mueller-Lisse
    Ulrike L. Mueller-Lisse
    World Journal of Urology, 2010, 28 : 253 - 261
  • [48] Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.
    Powles, Thomas
    Albiges, Laurence
    Jalkanen, Katriina Johanna
    De Velasco, Guillermo
    Burotto, Mauricio
    Ghatalia, Pooja
    Suarez, Cristina
    Lam, Elaine T.
    Iacovelli, Roberto
    Gumus, Mahmut
    Verzoni, Elena
    Kollmannsberger, Christian K.
    Stadler, Walter Michael
    Venugopal, Balaji
    Shinde, Reshma
    Saretsky, Todd L.
    He, Li
    Vickery, Donna
    Choueiri, Toni K.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 361 - 361
  • [49] Temsirolimus - In advanced renal cell carcinoma
    Simpson, Dene
    Curran, Monique P.
    DRUGS, 2008, 68 (05) : 631 - 638
  • [50] Treatment of advanced renal cell carcinoma
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2007, 49 (1276): : 103 - 104